Clinical trials
ctDNA clinical trials
Below are recruiting ctdna clinical trials, each written for real people, not researchers. We’re tracking 187 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06609551RecruitingPhase 3
ctDNA-guided chemo choice for elderly colon cancer patients
This trial tests whether using a ctDNA blood test can help choose the best chemotherapy after colon cancer surgery for people aged 70–80. It aims to make treatment more personalized and reduce side effects.
Hangzhou, ZhejiangAges 70–80 - NCT06614647Recruiting
Digital follow-up for colorectal cancer survivors
This trial tests a smartphone-based follow-up program for people who have been treated for early-stage colorectal cancer. The goal is to see if a digital, need-based care guide can replace standard follow-up visits.
Herning, Central JutlandAges 18 years+ - NCT06617858RecruitingPhase 2
AMB-05X for colorectal cancer with ctDNA after treatment
This trial tests a drug called AMB-05X for people with colorectal cancer who have completed all intended treatments and show no signs of cancer on scans, but still have cancer DNA (ctDNA) in their blood. The goal is to see if AMB-05X can eliminate this remaining cancer DNA and prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT06666439Recruiting
Tracking lobular breast cancer with a blood test
This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06693830Recruiting
Blood test guided treatment for newly diagnosed DLBCL
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
New York, New YorkAges 18 years+ - NCT06744296Recruiting
ctDNA surveillance for HPV-negative head and neck cancer
This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.
Boston, MassachusettsAges 18 years+ - NCT06755619Recruiting
ctDNA testing for response in first-line PCNSL treatment
This study tests whether a blood test (ctDNA) can help doctors see how well treatment is working for people with a type of brain lymphoma (PCNSL) who are getting their first treatment with a cure in mind.
HelsinkiAges 18–70 - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT06875609Recruiting
ctDNA test for skin cancer patients
This trial studies a blood test (ctDNA) in people with a type of skin cancer called cutaneous squamous cell carcinoma. It aims to see if the test can help track the cancer and guide treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT06885879Recruiting
Studying ctDNA changes after radiation for liver cancer
This trial studies how radiation therapy (SBRT) affects a DNA fragment in the blood called ctDNA in people with liver cancer. By tracking ctDNA changes, doctors hope to better understand how well the treatment is working and possibly predict outcomes earlier.
Hong KongAges 18 years+ - NCT06893133Recruiting
DNA testing after gastric cancer surgery
This study checks if a blood test can find leftover cancer DNA after stomach cancer surgery. It helps doctors know if more treatment is needed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06902012RecruitingPhase 1/Phase 2
Second infusion of CAR-T based on ctDNA for large B-cell lymphoma
This trial tests whether a second infusion of a CAR-T cell therapy called Axi-cel, given early based on a blood test (ctDNA), can help people with relapsed or hard-to-treat large B-cell lymphoma. If you had a partial response or your ctDNA stayed positive after the first dose, you may be eligible.
Guangzhou, GuangdongAges 18 years+ - NCT06903325Recruiting
Monitoring DNA markers in blood to predict colorectal cancer return after surgery
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06917573RecruitingPhase 2
Cemiplimab for advanced lung cancer with high PD-L1
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Alicante, AlicanteAges 18 years+ - NCT06929910Recruiting
K4Care test study for metastatic cancer patients
This study tests how well the K4Care blood test can monitor treatment in people with advanced solid tumors like lung, colorectal, breast, or stomach cancer that has spread. Researchers want to see if tracking tumor DNA in the blood helps guide therapy.
Ho Chi Minh City, Hồ Chí MinhAges Any age - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06954805RecruitingPhase 2
Study of ctDNA in PTLD after transplant
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
Stanford, CaliforniaAges 15 years+ - NCT06958107Recruiting
Liquid biopsy study for sarcoma patients
This study uses a simple blood test (liquid biopsy) to look for tiny pieces of tumor DNA in people with sarcoma. It may help doctors learn more about the disease and guide treatment decisions, whether you are just diagnosed, being treated, or have finished treatment recently.
Charlotte, North CarolinaAges Any age - NCT06977074RecruitingPhase 2
Personalized chemotherapy for lung cancer based on DNA test
This trial tests if a personalized treatment plan, guided by a blood test for tumor DNA, can improve outcomes for people with untreated, surgically removable lung cancer. It combines chemotherapy with immunotherapy before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07045571Recruiting
DNA blood test for pancreatic cancer prognosis and treatment
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
Shanghai, Shanghai MunicipalityAges Any age - NCT07054879Recruiting
Using a blood test to guide treatment after pancreatic cancer surgery
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
Nanjing, JiangsuAges 18 years+ - NCT07058012RecruitingPhase 2
Testing immunotherapy for ctDNA-positive colorectal cancer after treatment
This trial is for people with colorectal cancer whose ctDNA blood test is still positive after surgery and chemotherapy. It tests two immunotherapy drugs (cemiplimab alone or with fianlimab) to see if they can eliminate the remaining cancer cells and prevent the cancer from coming back.
Gainesville, FloridaAges 18 years+ - NCT07062016Recruiting
Studying high-risk endometrial cancer with blood and tissue tests
This trial studies tumor DNA in blood and tissue from people with aggressive endometrial cancer to better understand the disease. You donate samples during surgery and follow-up visits.
Rochester, MinnesotaAges 18 years+ - NCT07070648Recruiting
Predicting DLBCL treatment response with ctDNA and PET scans
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new ctDNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ctdna?
- Yes. Clin2 currently lists 187 recruiting ctdna studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ctdna trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ctdna trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.